Latest news and insights on the pharmaceutical industry | Indian Pharma Post | Page 111

Results For "CEP"

1789 News Found

Merck receives positive European Union CHMP opinion for Gefapixant
News | July 22, 2023

Merck receives positive European Union CHMP opinion for Gefapixant

The CHMP’s recommendation will now be reviewed by the European Commission for marketing authorization in the European Union


Merck receives positive EU CHMP opinion for pembrolizumab plus Trastuzumab and Chemotherapy as first-line treatment for HER2-positive advanced gastric or gastroesophageal junction
Drug Approval | July 22, 2023

Merck receives positive EU CHMP opinion for pembrolizumab plus Trastuzumab and Chemotherapy as first-line treatment for HER2-positive advanced gastric or gastroesophageal junction

If approved, KEYTRUDA would be the first immunotherapy for the first-line treatment of HER2-positive advanced gastric or GEJ cancer in tumors expressing PD-L1 (CPS ?1) in the EU


Tillotts Pharma and TVM Capital form Mage Biologics to develop oral antibody therapy for ulcerative colitis
News | July 21, 2023

Tillotts Pharma and TVM Capital form Mage Biologics to develop oral antibody therapy for ulcerative colitis

Mage Biologics to develop a monoclonal antibody targeting ulcerative colitis


Kintor Pharma completes first patient enrollment in long-term safety phase III trial of KX-826
News | July 21, 2023

Kintor Pharma completes first patient enrollment in long-term safety phase III trial of KX-826

The Long-term Safety Trial was approved to be conducted by China National Medical Products Administration (NMPA) on 18 April 2023


PrecisionLife identifies first detailed genetic risk factors for long COVID
News | July 19, 2023

PrecisionLife identifies first detailed genetic risk factors for long COVID

Long COVID is a debilitating chronic condition that has affected over 100 million people globally


Sumitomo Pharma America launches as new combined organization
News | July 11, 2023

Sumitomo Pharma America launches as new combined organization

SMPA's diverse portfolio includes six marketed products and a robust pipeline of early- to late-stage assets


Astellas receives FDA priority review for Zolbetuximab biologics license application
Drug Approval | July 10, 2023

Astellas receives FDA priority review for Zolbetuximab biologics license application

Astellas stands on the forefront of healthcare change to turn innovative science into value for patients


Sirolimus drug coated balloons is an alternative to stents, say Cardiologists
News | July 08, 2023

Sirolimus drug coated balloons is an alternative to stents, say Cardiologists

Especially valuable for young patients with multiple blocks & underlying conditions that may render angioplasty procedures with drug-eluting stents ineffective